| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528371 | Clinical Therapeutics | 2017 | 11 Pages |
Abstract
Future studies in treatment-refractory mCRC may be better served by evaluating improvement in symptom control and QOL, which may otherwise serve as the best predictor of survival in last-line treatment settings.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jun MD, Daniel MD, Jeremy MD, Richard MD, PhD, John PhD, Andrew MD,